CMRX Chimerix Inc

Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present a corporate overview at the following upcoming conferences:

• Stifel 2016 Healthcare Conference at 1:30 p.m. ET on Tuesday, November 15, 2016 at the Lotte New York Palace Hotel in New York
• 28th Annual Piper Jaffray Healthcare Conference at 11:30 a.m. ET on Wednesday, November 30, 2016 at the Lotte New York Palace Hotel in New York

A live audio webcast of each presentation will be available on the Investor Relations section of Chimerix’s website at www.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage compounds. Chimerix is also advancing a clinical candidate for norovirus infection, CMX521. For further information, please visit Chimerix's website www.chimerix.com.

CONTACT:
Investor Relations: 

ir@chimerix.com
or
Will O’Connor
Stern Investor Relations
Will@sternir.com 
212-362-1200
 
Media:

Becky Vonsiatsky
W2O Group
bvonsiatsky@w2ogroup.com
413-478-2003